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Introduction: Vasculopathy of the large vessels commonly occurs in sickle cell disease, and as a result cerebral
infarction is a well characterized complication of this condition. However, spinal infarction appears to be rare. Spinal
infarct is infrequent in the non-sickle cell population as well, and accounts for only about 1 percent of all central
nervous system infarcts.
Case presentation: In the present work, we report the case of a 19-year-old African-American man with sickle cell
disease who experienced an anterior spinal infarct and subsequent quadriplegia. He was incidentally noted to be a
heterozygote for factor V Leiden. We also reviewed the literature and found two previous cases of spinal cord
infarction and sickle hemoglobin. Our literature search did not demonstrate that heterozygocity for factor V Leiden
plays an important role in spinal cord infarction.
Conclusions: The paucity of cases associated with sickle hemoglobin does not allow us to postulate any particular
risk factors with sickle cell disease that might predispose patients to spinal cord infarction. Our patient’s case raises
the question as to whether spinal cord infarction is being missed in individuals with sickle cell disease and
neurologic symptoms.Introduction
Cerebral infarction is the most common neurologic
complication that occurs with sickle cell disease (SCD);
it can be either overt or silent and it can be associated
with significant morbidity [1]. Overt stroke in SCD was
first characterized in 1923, and histopathologic studies
later revealed large vessel narrowing with superimposed
thrombosis as the underlying cause [2,3]. Though cerebral
infarction is the most frequent neurological complication,
a number of other potentially devastating central nervous
system (CNS) sequelae have also been described. These
include: intra-cranial hemorrhage, isolated neuropathies,
transverse myelitis, auditory and ocular manifestations,
and spinal cord involvement [1]. In the spinal cord there* Correspondence: leila.clay@gru.edu
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reproduction in any medium, provided the orhas been a description of cord compression by extra-
medullary hemopoietic tissue in addition to rare case
reports of spinal cord infarction [1,4-6].
In the non-sickle cell disease population it appears
that spinal infarct is much less frequent than cerebral
infarction as well, and accounts for only about 1 percent
of all CNS infarcts [7]. Of those with spinal infarction,
most appear to be from traumatic or surgical etiologies
than other organic causes [7,8]. Aortic disease is a frequent
culprit with many case reports detailing adverse sequelae
following surgical repair of aneurysms, but also aortic
thrombosis, and aortic dissection [8]. Other non-traumatic,
non-surgical etiologies of spinal cord infarct include: global
hypotension and/or arterial insufficiency, often after
cardiac arrest; transient ischemic attacks; fibrocartilagenous
emboli; arterial vascular malformations; syphilitic arteritis
and adjacent spinal disease [8-10]. In a 2006 study,
Novy et al. noted that 12 of their 27 patients with spinal
infarct had pre-existing spinal disease including com-
pression fractures, spondylolisthesis, chronic aracho-
noiditis and chronic cervical disk protrusion, and of those
12 patients, 11 had an infarct at the level of their pre-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is frequently cryptogenic [11].
There is considerable evidence that sickle cell disease
represents a hypercoagulable state [12-15]. It appears
that nearly every component of hemostasis is altered
to some degree in SCD [15]. Studies have indicated
that in sickle cell disease there is increased platelet
activation and aggregation, increased levels of D-dimer
and fibrinogen and fibrin-fibrinogen complex while
there are simultaneously decreased factors V, VII, VIIa
and proteins C and S [13]. There is good evidence that
there is externalization of phosphatidylserine (a phospho-
lipid normally found in the inner monolayer of red blood
cells) in SCD, which is thought to play a significant role
in promoting macrophage recognition in erythropha-
gocytosis and thus triggering a signal for the coagulation
process [13,14]. Increased phosphatidylserine exposure
is also thought to be associated with increased tissue
factor expression [14]. However, it remains unclear how or
to what extent those abnormalities contribute to disease
complications such as cerebral and spinal infarcts.
Because cerebral infarcts occur only in a subset of the
sickle cell population, it has been postulated that there
may be identifiable features of this subgroup that exacer-
bate the hypercoagulable state of sickle cell disease. In
the search for possible characteristics of this subpopula-
tion, some have begun to explore factors that predispose
the general population to coagulation abnormalities and
thrombophilia. Specifically, there have been case reports
of persons with SCD who developed CNS infarcts and
were found to have the factor V Leiden, a prothrombin
gene variant, a methylenetetrahidrofolate reductase gene
mutation, or some combination of those mutations [16-18].
These studies were conducted in Brazil and Israel; not-
ably the prevalence of the factor V Leiden and the pro-
thrombin gene variant are known to be very low in
African-Americans [19]. Also, there have been a few
single nucleotide polymorphisms (SNPs) in persons
with SCD that have been found to be associated with
increased stroke risk: ANXA2, TGFBR3, and TEK were
noted in a study including these SNPs [20]. However,
further validation is needed before these can be used to
prospectively guide recommendations for molecular gen-
etic testing or treatment [20]. There is no known identi-
fiable thrombophilic abnormality that predicts cerebral
infarction in sickle cell disease.
Case presentation
On the morning of admission, our patient, a 19-year-old
African-American man with sickle cell anemia, felt
himself to be in his usual state of health, although he
had just been discharged the previous day from a
hospitalization for acute chest syndrome. He ate break-
fast and spent the day watching television. However, atapproximately 5:45 p.m. when he used the bathroom,
he noticed that he could not pull up his trousers due to
weakness in his left arm. As he walked out of the bath-
room, he noted that he was having difficulty walking
because of weakness in his right leg. As his mother was
helping him to his bed, his left leg also became weak.
He began experiencing ‘shocking’ pains on both sides
of his neck, which were unlike his usual pain, and also
noted that he had an erection. These events transpired
rapidly, within about six minutes, at which point his
family called Emergency Medical Services (EMS) and
our patient was transported to our hospital.
On arrival at our hospital, he was alert and oriented
and cranial nerves II to XII were intact. He had flaccid
paralysis of the bilateral upper extremities and the left
lower extremity, and normal tone with 5 out of 5
strength in the right lower extremity. He had areflexia in
the biceps, triceps, and brachioradialis bilaterally, hyper-
reflexia at the left patella, and sustained clonus at the left
Achilles. Sensation was intact throughout. The results of
the rest of his physical examination were normal.
Relevant medical history included asthma, recurrent
acute chest syndrome (>10 episodes), and intermittent
attempts at hydroxyurea treatment with poor compliance
over the previous 10 years. Following the identification
of silent cerebral infarcts, he was treated for the three
years between 2005 and 2008 with exchange transfusions
to maintain hemoglobin S < 30 percent; during this time
he did very well. At 10 days prior to presentation, he
was hospitalized with an acute chest syndrome. During
that hospitalization he had an initial PO2 of 76, a
hemoglobin (Hb)/hematocrit (Hct) nadir of 5.8/17, and
was found to have a methicillin-resistant Staphylococcus
aureus (MRSA) pneumonia. He was treated with antibi-
otics and a transfusion. His discharge hemoglobin was
6.6 and oxygen saturation 96 percent. He was without
symptoms at the time of discharge.
Admission laboratory test data included a white blood
cell count of 12 × 103/uL Hb 8.7g/dL, Hct 26 percent,
platelets 449 × 103 cells/mm3 with a hemoglobin elec-
trophoresis of HbA 86 percent, HbS 7 percent, and HbC
7 percent. He had a lumbar puncture that demonstrated
unremarkable cerebrospinal fluid findings and no evi-
dence of IgG oligoclonal bands. The results of peripheral
blood and urine cultures were negative. A chest X-ray
showed patchy consolidation in the right upper lobe
suspicious for pneumonia. The results of computed
tomography (CT) angiography of the head and neck
were unremarkable. Given concern for spinal cord in-
volvement, 1.5T T1, T2, and fluid attenuated inversion
recovery (FLAIR) magnetic resonance imaging (MRI)
studies of the brain and cervical spine was performed
showing an abnormal T2/FLAIR signal in the cervical
spinal cord, which was thought at that time likely to be
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show swelling of the cord in the same area. He was
admitted to the neurologic intensive care unit where he
received an exchange transfusion with no significant
improvement in his symptoms; subsequent hemoglobin
electrophoresis showed HbA 85 percent, HbS 9 percent.
While in the intensive care unit (ICU) he experienced
episodes of hypotension that were initially managed with
vasopressors. After his blood pressure stabilized he was
transitioned to fludrocortisone and midodrine. He never
had respiratory insufficiency. Two days after admission
he had a repeat MRI, which showed T2 hyperintense
signal extending from C2 through to C7 (Figure 1A). In
addition, diffusion-weighted imaging demonstrated re-
stricted diffusion consistent with a focus of infarction
in addition to cord edema and swelling in the gray and
white matter of the right side of the cord. There was
associated enlargement of the spinal cord consistent
with edema from the anterior spinal infarct. A hyperco-
agulability investigation performed during his hospital-
ization included a polymerase chain reaction (PCR)
study that demonstrated that he was heterozygous for
the factor V Leiden 1691 G>A mutation. Other studies
performed were for factor VIII, fibrinogen, functional
anti-thrombin, lupus anti-coagulant, anti-cardiolipin,
all of which were within normal limits. His erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)
levels were both elevated, and proteins C and S were
found to be low but within the expected range for some-
one with sickle cell disease. He was anti-coagulated withFigure 1 A,B T2 hyperintense signal extending from C2 to C7 with ed
the edema. As with all infarcts, the area of infarct is bright on B1000 and da heparin drip during his stay in the acute care facility, but
this was discontinued on discharge. A monthly exchange
transfusion regimen was instituted with the goal of keep-
ing his hemoglobin S level < 30 percent.
Although initially there was almost complete paralysis
of his extremities, over the four days he spent in the
neurologic ICU, our patient demonstrated slow but
steady progress in regaining some motor function of his
affected limbs. He was transferred from the ICU to the
wards on day five and began working with physical and
occupational therapy. On day 10, he was transferred to a
rehabilitation facility, where he made gradual but steady
progress in regaining motor function. He was discharged
home after three weeks.
Five months after the acute onset of paralysis, he had
some residual left arm and leg weakness and spasticity,
but was able to walk unassisted and perform most ac-
tivities of daily living without assistance. A repeat MRI
scan showed a persistence of slight T2 signal abnormal-
ity in the cervical cord, consistent with previous spinal
cord infarction. There was no spinal cord atrophy (Figure 2).
Our patient continued to make progress, regaining much
of his strength and function, and was maintained on a
regimen of monthly scheduled exchange transfusions.
At 18 months post-infarct he presented with complaints
of three hours of generalized weakness, worse in his lower
extremities in association with a pain crisis. His symptoms
of weakness had largely resolved by the time he arrived
at our Emergency Department. On examination he had
4 out of 5 strength in his left lower extremity and 5 outema of the gray and white matter of the cord. The arrows point to
ark on apparent diffusion coefficient sequences.
Figure 2 A,B Follow-up magnetic resonance imaging study demonstrating no spinal cord atrophy with residual signal from
myelomalacia, months after infarct. Arrows point to the decrease in edema.
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strength bilaterally with a slightly unsteady gait; these
findings were not substantially different from his post-
spinal cord infarction baseline. His hemoglobin S was
51.5 percent at that time. Repeat imaging studies of his
brain and spine at that time were unchanged from his
prior studies. He was admitted and had an exchange
transfusion achieving a post-transfusion HbS of 8.3
percent. He was given daily low-dose (81mg) aspirin.
Currently, at 20 months post-spinal cord infarction, his
condition is unchanged.
Discussion
Spinal cord infarct is infrequent compared to cerebral in-
farction in the general population, and most commonly
occurs as a result of a dissecting aortic aneurysm or aortic
surgery [7,8]. In persons with sickle hemoglobin, sig-
nificant spinal cord infarction appears to be an even
more rare neurologic complication. To the best of our
knowledge, there are only two reported cases of other
persons, both now deceased, detailing this pathology
[4,5]. Of note, the radiographic findings from our patient
have been previously presented in a radiology journal
with emphasis on the diffusion-weighted images, but in
this report we describe the clinical details and our patient’s
subsequent course [6].
There is a case report from 1970 of a 59-year-old Jamaican
woman with presumed sickle cell trait who deteriorated
over the course of several years to near complete paraplegia
and who was subsequently found to have a slightly swollen
spinal cord in the cervical region and atrophic thoracic
and lumbar spine cord segments on autopsy [4]. The au-
thors noted that her vasculature and neural tissue was
otherwise without the stigmata of significant atherosclerotic
or degenerative disease, and while no thrombosed ves-
sels were found in relation to the areas of necrosis inher spinal cord, there were however, many arteries
and veins distended with abnormally shaped sickle red
cells [4]. A 1980 case report describes a 19-year-old
African-American man with sickle cell disease who devel-
oped sudden-onset quadriplegia and in post-mortem stud-
ies was found to have multiple, old, focal and confluent
infarcts involving the cortex and subcortical white matter
in the brain, and also of the cervical, thoracic, and upper
lumbar spinal cord [5]. There are no data from these
case reports in the literature concerning other potential
risk factors including any thrombophilic abnormalities, as
these were not commonly looked for in 1970 and 1980.
From the available reports that have looked for an
association between factor V Leiden and complications
of sickle cell disease, there is no evidence of an obvious
relationship [16,21,22]. Kahn et al. studied a cohort of
82 patients with different sickle cell states, 19 of whom
had had a stroke [21]. Only one of the 82 was heterozy-
gous for factor V Leiden (there were no homozygotes),
and this was not a patient who had experienced a
stroke, priapism or any other vascular-type disorder
[21]. Andrade et al. similarly examined a cohort of 73
patients with sickle cell disease in Brazil, of whom five
had a stroke [16]. One of the five was a heterozygote for
factor V Leiden; of the patients who had not experienced
a stroke, none were positive for the factor V Leiden muta-
tion. Interestingly, that patient had a sister who also
had sickle cell anemia and stroke, but the sister did not
carry the factor V Leiden mutation. We conclude that our
patient’s heterozygosity for factor V Leiden did not con-
tribute to the occurrence of the spinal cord infarction.
Our patient has severe sickle cell disease as manifested
by multiple bouts of recurrent acute chest syndrome and
the presence of a silent cerebral infarction. As a comorbid-
ity which predisposes to more severe disease, he also has
asthma. However, he would not be considered to be very
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question arises as to why he developed the rare compli-
cation of spinal cord infarction. It occurred during the
recovery from an episode of acute chest syndrome,
which is known to be a time period of increased risk for
cerebral infarction, but this is clearly not a full explanation
given the frequency of acute chest syndrome and the rarity
of spinal cord infarction. His hypoxemia had resolved
when the spinal cord infarction occurred, and his wors-
ened anemia had been corrected. In addition, his sickle
hemoglobin percentage was quite low. Although our
review of the literature does not suggest that his infarct
can be explained by the factor V Leiden heterozygosity,
he was not tested for any of the other genetic variants
that have been recently found to be associated with
stroke in SCD such as ANXA2, TGFBR3, and TEK. It is
possible that a combination of factor V Leiden hetero-
zygosity and another mutation may increase his risk for
this complication. However, in order to determine risk
factors for this complication, its true incidence in SCD
must be known.
Conclusions
It is possible that spinal cord infarction may occur more
commonly than previously recognized in sickle cell disease
and is missed or misdiagnosed as cerebral infarction.
Although in our patient’s case there were clear findings
suggestive of spinal cord involvement, some presentations
could be more subtle, and many clinicians may not think
of the spinal cord when a patient with sickle cell presents
with neurologic deficits. We hope that this report may
lead others who care for people with sickle cell disease
to be vigilant to the possibility of central nervous system
infarction involving the spinal cord.
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